Brief: Eagle Pharmaceuticals Takes Equity Stake In, With Option To Acquire, Enalare Therapeutics
09/08/2022 13:07
Aug 9 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS TAKES EQUITY STAKE IN, WITH OPTION
TO
ACQUIRE, ENALARE THERAPEUTICS TO ADVANCE GLOBAL DEVELOPMENT OF
ENA-001, A NOVEL AGNOSTIC RESPIRATORY STIMULANT
* EAGLE PHARMACEUTICALS INC - APPROVAL FOR POST-OPERATIVE
RESPIRATORY DEPRESSION EXPECTED IN 2026 AND COMMUNITY DRUG
OVERDOSE THEREAFTER
* EAGLE PHARMACEUTICALS INC - WILL MAKE A $25 MILLION
INVESTMENT
IN ENALARE THERAPEUTICS
* EAGLE PHARMACEUTICALS INC - TWO COMPANIES ALSO ENTERED
INTO AN
AGREEMENT PROVIDING EAGLE OPTION TO ACQUIRE REMAINING
OUTSTANDING SHARES
* EAGLE PHARMACEUTICALS INC - ENA-001 IS EXPECTED TO ENTER A
PHASE
2 STUDY WITH FIRST PATIENT BY EARLY 2023
Source text for Eikon: ID:nGNX3dtMbY
Further company coverage: EGRX.O
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq